Related Experiment Video
Updated: Jun 23, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
[Irreversible, non-selective monoamine oxidase inhibitors]
Ingrid Castberg1, Olav Spigset
1Psykisk helsevern avdeling Østmarka, St. Olavs hospital, Postboks 3008 Lade, 7441 Trondheim. ingrid.castberg@stolav.no
Summary
Monoamine oxidase (MAO) inhibitors are early antidepressants. This review details their adverse effects, interactions, and precautions for physicians managing patients on these medications.
Area of Science:
- Pharmacology
- Neuroscience
- Psychiatry
Context:
- Irreversible, non-selective monoamine oxidase (MAO) inhibitors represent a historical class of antidepressants.
- While not currently marketed in Norway, these drugs are accessible via named patient applications.
- Physicians frequently encounter patients using MAO inhibitors, necessitating awareness of their clinical profile.
Purpose:
- To present a comprehensive overview of the adverse effects associated with irreversible, non-selective monoamine oxidase inhibitors.
- To detail the potential drug and food interactions relevant to monoamine oxidase inhibitor therapy.
- To outline essential precautions for the safe clinical use of these antidepressants.
Summary:
- Adverse effects of irreversible, non-selective monoamine oxidase inhibitors range from common side effects to serious events.
- Significant interactions with certain foods (tyramine-rich) and medications can lead to hypertensive crises or serotonin syndrome.
- Careful patient selection, monitoring, and adherence to dietary and drug restrictions are crucial for managing risks.
Impact:
- Enhances clinical understanding of managing patients on older antidepressant classes.
- Provides essential information for healthcare professionals to mitigate risks associated with monoamine oxidase inhibitors.
- Supports safer prescribing practices and improved patient outcomes for individuals using these medications.
More Related Videos
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...